AlphAIAlphAI — Financial news for AI agents
investing.comOCT 162 min read$IBRX

ImmunityBio reports long-term bladder cancer treatment data

ImmunityBio (IBRX) published long-term data from its Phase 2/3 study on ANKTIVA for bladder cancer, showing 71% complete response rate and 98.2% disease-specific survival at three years. The treatment received FDA approval in 2024, with an expanded indication this month. The study reported no severe adverse events, with most being localized bladder symptoms.

Original reporting
investing.com
Published Oct 16, 2026, 3:52 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 16, 2026, 3:59 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$IBRX
Bullish
high confidence
Mentioned
$IBRX
Relevance
9/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$IBRXBullishHigh
01

Why it matters

The data represent the first public disclosure of these long‑term outcomes, a material catalyst for the stock.

02

Market read

New pivotal trial data can drive significant price movement for IBRX.

03

What to watch

Long-term safety profile and commercial rollout timeline could temper enthusiasm.

Relevance 9/10Novelty 9/10Timing: pre-market today

Background

ImmunityBio (NASDAQ:IBRX) announced Phase 2/3 QUILT-3.032 data for ANKTIVA in BCG‑unresponsive non‑muscle invasive bladder cancer.

Company-level read

Ticker impact

$IBRXBullishHigh confidence
Context

ImmunityBio released long-term Phase 2/3 bladder cancer trial data showing 71% complete response and durable outcomes.

Expected impact

upward pressure as market prices in the positive efficacy data

Evidence & confidence

High response rates and durable survival metrics are material for a biotech, prompting buying interest.

Market effects

Sector

May lift sentiment for bladder cancer therapeutics and related biotech peers.

Regional

U.S. biotech sector could see modest gains.

Global

Limited to biotech investors; no broad market effect.

Counterpoint

What could challenge this read

Some investors may wait for FDA filing updates before committing.

Key entities

  • company
    ImmunityBio, Inc.

    Biotech firm developing bladder cancer therapies.

Read at source← All news

StoryFDA broadens ImmunityBio’s ANKTIVA bladder cancer approval

Also covered by

4 outlets

Related articles

OCT 15
$IBRXHighAI 8/10

H.C. Wainwright reiterates Immunitybio stock rating on FDA approval expansion

H.C. Wainwright reiterated a Buy rating and $15.00 price target on Immunitybio (IBRX) after FDA expanded ANKTIVA's approval. The stock is up 400% YTD to $9.91, with a $10.5B market cap. The FDA approved ANKTIVA for high-risk BCG-unresponsive NMIBC papillary-only disease, representing 60% of such patients. Analysts expect sales growth. Immunitybio also received marketing authorization in the UAE for ANKTIVA.

investing.com2 min
OCT 15
HighAI 9/10

ImmunityBio’s bladder cancer drug, Anktiva lands US label expansion

ImmunityBio's drug Anktiva gained US label expansion for bladder cancer without needing a separate Phase III trial. The FDA initially requested this but later agreed it wasn't necessary. Johnson & Johnson is running a Phase III trial for its NMIBC therapy Inlexzo. Anktiva is expected to reach blockbuster status by 2029 and generate over $4bn in global sales by 2032, according to GlobalData.

finance.yahoo.com2 min
OCT 14
$IBRXHighAI 9/10

ImmunityBio: FDA expands ANKTIVA approval to include papillary-only BCG-unresponsive NMIBC

ImmunityBio (IBRX) announced the FDA expanded ANKTIVA's approval to include BCG-unresponsive non-muscle invasive bladder cancer patients with papillary-only tumors. The expanded label now covers all BCG-unresponsive NMIBC patients. Clinical data showed a 62% complete response rate, with 58% of responders maintaining the response for at least 12 months. The safety profile was consistent with BCG instillation.

tradingview.com1 min
OCT 14
$IBRXHighAI 8/10

ImmunityBio, Inc. (IBRX): FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle- Invasive Bladder Cancer to Cover Both Papillary and CIS Disease

ImmunityBio, Inc. (IBRX) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 NEWS RELEASE FDA Expands ANKTIVA ® Approval for BCG-Unresponsive Non-Muscle- Invasive Bladder Cancer to Cover Both Papillary and CIS Disease • Expanded indication extends ANKTIVA plus BCG to patients with BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC), i

SEC EDGAR 8-K2 min